Johnson & Johnson Innovation - JJDC’s Aldeyra Therapeutics ALDX Stock Holding History

Johnson & Johnson Innovation - JJDC’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$4.47M	Hold	394,834	–	–	0.46%	13
2021 Q1	$4.69M	Sell	394,834 -200,000	-34%	-$2.3M	0.61%	11
2020 Q4	$4.08M	Hold	594,834	–	–	0.53%	10
2020 Q3	$4.41M	Hold	594,834	–	–	0.89%	11
2020 Q2	$2.48M	Hold	594,834	–	–	0.49%	10
2020 Q1	$1.47M	Hold	594,834	–	–	0.8%	7
2019 Q4	$3.46M	Buy	+594,834	New	+$3.44M	1.25%	6

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Johnson & Johnson Innovation - JJDC's ALDX Position: Q2 2021 in Review

Johnson & Johnson Innovation - JJDC held its Aldeyra Therapeutics (ALDX) position steady in Q2 2021 at 394,834 shares worth $4.47M. The position accounts for 0.46% of the portfolio, ranked #13.

Johnson & Johnson Innovation - JJDC first reported a position in ALDX in Q4 2019 and has held it in 7 quarters since. The position peaked at $4.69M in Q1 2021. 136 funds tracked by Wall St. Rank hold ALDX as of Q2 2021.

Johnson & Johnson Innovation - JJDC held 394,834 shares of Aldeyra Therapeutics worth $4.47M as of Q2 2021.
Johnson & Johnson Innovation - JJDC left its Aldeyra Therapeutics share count unchanged in Q2 2021.
Aldeyra Therapeutics made up 0.46% of Johnson & Johnson Innovation - JJDC's portfolio in Q2 2021, its #13 holding.
Johnson & Johnson Innovation - JJDC first reported a position in Aldeyra Therapeutics in Q4 2019 and has held it in 7 quarters since.
Johnson & Johnson Innovation - JJDC's Aldeyra Therapeutics position peaked at $4.69M in Q1 2021.
136 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2021.

Based on Johnson & Johnson Innovation - JJDC's 13F filing for Q2 2021, filed 3 Aug 2021.